The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

The invention relates to a process for preparing optically active 2-aryl substituted 6,7-dihydro-5H-cyclopenta[b]pyridin-7-ols comprising asymmetric transfer hydrogenation of the corresponding ketones in presence of a ruthenium catalyst comprising a chiral diamine or amino alcohol ligand.

The invention relates to a process for preparing optically active 2-aryl substituted 6,7-dihydro-5H-cyclopenta[b]pyridin-7-ols comprising asymmetric transfer hydrogenation of the corresponding ketones in presence of a ruthenium catalyst comprising a chiral diamine or amino alcohol ligand.

Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

The invention relates to a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.

##STR00001##

The invention relates to a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.

##STR00001##

The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.